Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Stock Picking for Charity - 2004 -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (146)	1/12/2004 9:43:34 AM
From: zeta1961	Respond to of 346

I can see why! As a critical care nurse, I can vouch with certainty that today's news on dalbavancin will be embraced by many... MICU slipped past my radar...vancomycin is also used for long term therapy(6-8wks) for bone infections for example...these patients have to carry and manage this medication 24/7...dalbavancin will preclude this nuisance...huge market share possibilities.. Congrats on the find...will keep it on my personal radar... Zeta

To: Arthur Radley who wrote (146)	1/12/2004 10:26:13 AM
From: Biomaven	Respond to of 346

<MICU> I agree these are very good-looking results (and I own a little in real life). But the very long half-life (9-12 days based on what I have read) to my mind raises similar safety concerns that have been expressed about oritavancin - if you ever do get a drug reaction in some patient, the drug will still remain onboard for weeks. Peter P.S. I don't know if people want to use this thread as a discussion place for the stocks in the portfolios or not. If not, then discussion is of course always welcome over on the Valuation thread.